Company Cash and Cash Equivalents Reach $10.2 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy INTS?
Cash and cash equivalents of $10.2M as of March 31. Lewis Bender, Founder, President, and CEO, stated, "The Company made excellent progress in the first quarter. We announced early data from the INVINCIBLE-4 Study, our randomized controlled study in TNBC, showing the possibilities for INT230-6 to increase efficacy while also potentially improving safety. We are now seeking additional patients in our INVINCIBLE-4 Study in Switzerland and expect to initiate enrollment in France in the second or third quarter of 2026. Further, after a successful funding campaign in 2025 and the establishment of a $60 million ATM facility in March 2026, we have made the decision to reinitiate enrollment of our INVINCIBLE-3 Study and plan to manage our cash burn judiciously. Both of our clinical trials focus on indications with high unmet medical need."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INTS
Wall Street analysts forecast INTS stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.110
Low
1.50
Averages
3.33
High
5.00
Current: 5.110
Low
1.50
Averages
3.33
High
5.00
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intensity Therapeutics Reports Q1 2026 Financial Results
- Financial Performance: Intensity Therapeutics reported a GAAP EPS of -$0.96 for Q1 2026, indicating challenges in profitability that may impact investor confidence moving forward.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $10.2 million, which, while providing some liquidity, raises concerns about its ongoing operational capacity and future financing needs.
- Market Reaction: The reported losses have led to a cautious market sentiment regarding Intensity Therapeutics' future prospects, potentially resulting in stock price volatility and affecting investor decisions.
- Financial Transparency: The financial information and historical earnings data provided by the company assist analysts and investors in assessing its financial health, but the sustainability of its profitability model remains a critical concern.
See More
Intensity Therapeutics Wins Platinum Award for Biotech Innovation
- Award Recognition: Intensity Therapeutics has been awarded the Platinum Award for its intratumoral injection platform and lead drug candidate INT230-6 at the 2026 Pinnacle Awards, highlighting the company's innovative capabilities and impact in the biotech solutions sector.
- Drug Development Progress: INT230-6 combines two potent anti-cancer agents, cisplatin and vinblastine sulfate, utilizing non-covalent drug conjugation technology to rapidly disperse and penetrate cancer cells within tumors, which is expected to significantly enhance treatment efficacy across multiple solid tumor indications.
- Clinical Trial Results: The company has completed two clinical studies involving over 200 patients, demonstrating the effectiveness of INT230-6 in metastatic cancers and locally advanced breast cancer, with plans to advance into a Phase 3 trial for soft tissue sarcoma.
- Future Treatment Outlook: The unique mechanism of INT230-6 holds the potential to shift cancer treatment from a short-term death sentence to chronic disease management, particularly for malignancies unresponsive to immunotherapy, presenting significant clinical and market potential.
See More
Intensity Therapeutics Wins Platinum Award for Biotech Innovation
- Award Recognition: Intensity Therapeutics has been awarded the Platinum Award for its intratumoral injection platform and lead drug candidate INT230-6 at the 2026 Pinnacle Awards, highlighting its innovative capabilities in biotech solutions, which may enhance the company's reputation and competitiveness in the cancer treatment market.
- Product Candidate Advantages: INT230-6 combines two potent anti-cancer agents, cisplatin and vinblastine sulfate, utilizing a non-covalent conjugation technology that facilitates rapid drug dispersion within tumors, potentially leading to significantly improved treatment outcomes and patient survival rates.
- Clinical Trial Progress: The company has completed two clinical studies involving over 200 patients, with an ongoing Phase 3 trial comparing INT230-6 to standard care in soft tissue sarcoma, which, if successful, could provide significant market opportunities for the company.
- Future Development Potential: The company aims to combine INT230-6 with standard therapies to transform the treatment landscape for many deadly cancers into chronic diseases, further driving strategic growth in the biotechnology sector.
See More
Intensity Therapeutics Reports FY Losses
- Disappointing Earnings: Intensity Therapeutics reported a FY GAAP EPS of -$8.56, missing expectations by $0.69, indicating significant challenges in profitability that could undermine investor confidence.
- Cash Position: As of December 31, 2025, the company had $11.9 million in cash and cash equivalents, which, while providing some liquidity, raises concerns about its ongoing operational capacity and future financing needs.
- Market Reaction Outlook: Given the earnings miss, the stock price of Intensity Therapeutics is expected to face downward pressure, prompting investors to reassess the company's growth potential and associated risks.
- Analyst Rating Focus: Increased market attention on Intensity Therapeutics is likely, with Seeking Alpha's Quant Rating serving as a critical reference for investors evaluating the company's outlook, especially in light of its current financial struggles.
See More
Intensity Therapeutics Reports 2025 Year-End Financial Results and Corporate Update
- Financial Improvement: In 2025, Intensity Therapeutics raised over $20 million through two public offerings and ATM issuances, resulting in cash and cash equivalents of $11.9 million, extending its operating runway into Q2 2027, indicating positive progress in capital raising efforts.
- Clinical Trial Progress: The INVINCIBLE-3 study paused new patient enrollments due to funding constraints but had enrolled 21 patients and continues treatment, with plans to resume enrollment in 2026, demonstrating the company's ongoing commitment to clinical research.
- Reduced R&D Expenses: Research and development expenses for 2025 were $6.8 million, down from $10.5 million in 2024, primarily due to lower costs associated with the INVINCIBLE-3 study, reflecting effective cost control measures by the company.
- Decreased Net Loss: The net loss for 2025 was $11.6 million, compared to $16.3 million in 2024, indicating improvements in financial management and operational efficiency.
See More
Intensity Therapeutics Reports 2025 Financial Results and Study Updates
- Capital Raising Success: In 2025, Intensity Therapeutics raised over $20 million through two public offerings and ATM issuances, resulting in cash and cash equivalents of $11.9 million as of December 31, 2025, which extends the company's operational runway into the second quarter of 2027, thereby enhancing financial stability.
- Clinical Study Results: In the INVINCIBLE-4 study, 71.4% (5 out of 7) of early-stage triple-negative breast cancer patients receiving INT230-6 achieved a pathological complete response (pCR), compared to only 33% (2 out of 6) in the control group, indicating the potential efficacy of INT230-6 and its ability to change treatment standards.
- Safety Analysis: The INVINCIBLE-4 study observed a 44% reduction in grade 3 or higher adverse events among patients receiving INT230-6, suggesting a significant safety advantage for this treatment regimen, which may enhance patient compliance.
- Published Research Impact: Results from the IT-01 study of INT230-6 were published in eBioMedicine, showing a 75% disease control rate and a median overall survival of 11.9 months in 64 heavily pretreated patients, surpassing historical data and emphasizing the therapy's potential in treating metastatic cancers.
See More
Intensity Therapeutics Reports Q1 2026 Financial Results
- Financial Performance: Intensity Therapeutics reported a GAAP EPS of -$0.96 for Q1 2026, indicating challenges in profitability that may impact investor confidence moving forward.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $10.2 million, which, while providing some liquidity, raises concerns about its ongoing operational capacity and future financing needs.
- Market Reaction: The reported losses have led to a cautious market sentiment regarding Intensity Therapeutics' future prospects, potentially resulting in stock price volatility and affecting investor decisions.
- Financial Transparency: The financial information and historical earnings data provided by the company assist analysts and investors in assessing its financial health, but the sustainability of its profitability model remains a critical concern.
See More
Intensity Therapeutics Wins Platinum Award for Biotech Innovation
- Award Recognition: Intensity Therapeutics has been awarded the Platinum Award for its intratumoral injection platform and lead drug candidate INT230-6 at the 2026 Pinnacle Awards, highlighting the company's innovative capabilities and impact in the biotech solutions sector.
- Drug Development Progress: INT230-6 combines two potent anti-cancer agents, cisplatin and vinblastine sulfate, utilizing non-covalent drug conjugation technology to rapidly disperse and penetrate cancer cells within tumors, which is expected to significantly enhance treatment efficacy across multiple solid tumor indications.
- Clinical Trial Results: The company has completed two clinical studies involving over 200 patients, demonstrating the effectiveness of INT230-6 in metastatic cancers and locally advanced breast cancer, with plans to advance into a Phase 3 trial for soft tissue sarcoma.
- Future Treatment Outlook: The unique mechanism of INT230-6 holds the potential to shift cancer treatment from a short-term death sentence to chronic disease management, particularly for malignancies unresponsive to immunotherapy, presenting significant clinical and market potential.
See More
Intensity Therapeutics Wins Platinum Award for Biotech Innovation
- Award Recognition: Intensity Therapeutics has been awarded the Platinum Award for its intratumoral injection platform and lead drug candidate INT230-6 at the 2026 Pinnacle Awards, highlighting its innovative capabilities in biotech solutions, which may enhance the company's reputation and competitiveness in the cancer treatment market.
- Product Candidate Advantages: INT230-6 combines two potent anti-cancer agents, cisplatin and vinblastine sulfate, utilizing a non-covalent conjugation technology that facilitates rapid drug dispersion within tumors, potentially leading to significantly improved treatment outcomes and patient survival rates.
- Clinical Trial Progress: The company has completed two clinical studies involving over 200 patients, with an ongoing Phase 3 trial comparing INT230-6 to standard care in soft tissue sarcoma, which, if successful, could provide significant market opportunities for the company.
- Future Development Potential: The company aims to combine INT230-6 with standard therapies to transform the treatment landscape for many deadly cancers into chronic diseases, further driving strategic growth in the biotechnology sector.
See More
Intensity Therapeutics Reports FY Losses
- Disappointing Earnings: Intensity Therapeutics reported a FY GAAP EPS of -$8.56, missing expectations by $0.69, indicating significant challenges in profitability that could undermine investor confidence.
- Cash Position: As of December 31, 2025, the company had $11.9 million in cash and cash equivalents, which, while providing some liquidity, raises concerns about its ongoing operational capacity and future financing needs.
- Market Reaction Outlook: Given the earnings miss, the stock price of Intensity Therapeutics is expected to face downward pressure, prompting investors to reassess the company's growth potential and associated risks.
- Analyst Rating Focus: Increased market attention on Intensity Therapeutics is likely, with Seeking Alpha's Quant Rating serving as a critical reference for investors evaluating the company's outlook, especially in light of its current financial struggles.
See More
Intensity Therapeutics Reports 2025 Year-End Financial Results and Corporate Update
- Financial Improvement: In 2025, Intensity Therapeutics raised over $20 million through two public offerings and ATM issuances, resulting in cash and cash equivalents of $11.9 million, extending its operating runway into Q2 2027, indicating positive progress in capital raising efforts.
- Clinical Trial Progress: The INVINCIBLE-3 study paused new patient enrollments due to funding constraints but had enrolled 21 patients and continues treatment, with plans to resume enrollment in 2026, demonstrating the company's ongoing commitment to clinical research.
- Reduced R&D Expenses: Research and development expenses for 2025 were $6.8 million, down from $10.5 million in 2024, primarily due to lower costs associated with the INVINCIBLE-3 study, reflecting effective cost control measures by the company.
- Decreased Net Loss: The net loss for 2025 was $11.6 million, compared to $16.3 million in 2024, indicating improvements in financial management and operational efficiency.
See More
Intensity Therapeutics Reports 2025 Financial Results and Study Updates
- Capital Raising Success: In 2025, Intensity Therapeutics raised over $20 million through two public offerings and ATM issuances, resulting in cash and cash equivalents of $11.9 million as of December 31, 2025, which extends the company's operational runway into the second quarter of 2027, thereby enhancing financial stability.
- Clinical Study Results: In the INVINCIBLE-4 study, 71.4% (5 out of 7) of early-stage triple-negative breast cancer patients receiving INT230-6 achieved a pathological complete response (pCR), compared to only 33% (2 out of 6) in the control group, indicating the potential efficacy of INT230-6 and its ability to change treatment standards.
- Safety Analysis: The INVINCIBLE-4 study observed a 44% reduction in grade 3 or higher adverse events among patients receiving INT230-6, suggesting a significant safety advantage for this treatment regimen, which may enhance patient compliance.
- Published Research Impact: Results from the IT-01 study of INT230-6 were published in eBioMedicine, showing a 75% disease control rate and a median overall survival of 11.9 months in 64 heavily pretreated patients, surpassing historical data and emphasizing the therapy's potential in treating metastatic cancers.
See More
